Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Common genetic variants in prostate cancer risk prediction--results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3).

Lindström S, Schumacher FR, Cox D, Travis RC, Albanes D, Allen NE, Andriole G, Berndt SI, Boeing H, Bueno-de-Mesquita HB, Crawford ED, Diver WR, Gaziano JM, Giles GG, Giovannucci E, Gonzalez CA, Henderson B, Hunter DJ, Johansson M, Kolonel LN, Ma J, Le Marchand L, Pala V, Stampfer M, Stram DO, Thun MJ, Tjonneland A, Trichopoulos D, Virtamo J, Weinstein SJ, Willett WC, Yeager M, Hayes RB, Severi G, Haiman CA, Chanock SJ, Kraft P.

Cancer Epidemiol Biomarkers Prev. 2012 Mar;21(3):437-44. doi: 10.1158/1055-9965.EPI-11-1038. Epub 2012 Jan 11.

2.

Genetic predisposition to prostate cancer.

Benafif S, Eeles R.

Br Med Bull. 2016 Dec;120(1):75-89. Epub 2016 Oct 6. Review.

PMID:
27941040
3.

Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis.

Louie KS, Seigneurin A, Cathcart P, Sasieni P.

Ann Oncol. 2015 May;26(5):848-64. doi: 10.1093/annonc/mdu525. Epub 2014 Nov 17. Review.

PMID:
25403590
4.

The role of genetic markers in the management of prostate cancer.

Choudhury AD, Eeles R, Freedland SJ, Isaacs WB, Pomerantz MM, Schalken JA, Tammela TL, Visakorpi T.

Eur Urol. 2012 Oct;62(4):577-87. doi: 10.1016/j.eururo.2012.05.054. Epub 2012 Jun 5. Review.

PMID:
22695242
5.

Promise and challenge: Markers of prostate cancer detection, diagnosis and prognosis.

Troyer DA, Mubiru J, Leach RJ, Naylor SL.

Dis Markers. 2004;20(2):117-28. Review.

6.

Prostate cancer family history and eligibility for active surveillance: a systematic review of the literature.

Telang JM, Lane BR, Cher ML, Miller DC, Dupree JM.

BJU Int. 2017 Oct;120(4):464-467. doi: 10.1111/bju.13862. Epub 2017 May 3. Review.

PMID:
28371016
7.

A genetic-based approach to personalized prostate cancer screening and treatment.

Helfand BT, Catalona WJ, Xu J.

Curr Opin Urol. 2015 Jan;25(1):53-8. doi: 10.1097/MOU.0000000000000130. Review.

8.

Multigene panels in prostate cancer risk assessment: a systematic review.

Little J, Wilson B, Carter R, Walker K, Santaguida P, Tomiak E, Beyene J, Usman Ali M, Raina P.

Genet Med. 2016 Jun;18(6):535-44. doi: 10.1038/gim.2015.125. Epub 2015 Oct 1. Review.

PMID:
26426883
9.

Epidemiology, etiology, diagnosis and treatment of prostate cancer.

Daniyal M, Siddiqui ZA, Akram M, Asif HM, Sultana S, Khan A.

Asian Pac J Cancer Prev. 2014;15(22):9575-8. Review.

10.

Biomarkers for the detection and prognosis of prostate cancer.

Hernandez J, Canby-Hagino E, Thompson IM.

Curr Urol Rep. 2005 May;6(3):171-6. Review.

PMID:
15869720
11.

A comparison of genetic risk score with family history for estimating prostate cancer risk.

Helfand BT.

Asian J Androl. 2016 Jul-Aug;18(4):515-9. doi: 10.4103/1008-682X.177122. Review.

12.

Impact of Candidate Genetic Polymorphisms in Prostate Cancer: An Overview.

Salvi S, Conteduca V, Gurioli G, Calistri D, Casadio V, De Giorgi U.

Mol Diagn Ther. 2016 Feb;20(1):1-12. doi: 10.1007/s40291-015-0169-9. Review.

PMID:
26518421
13.

Molecular markers in urologic oncology: prostate cancer.

Reichard CA, Stephenson AJ, Klein EA.

Curr Opin Urol. 2016 May;26(3):225-30. doi: 10.1097/MOU.0000000000000273. Review.

PMID:
26825652
14.

Molecular Profiles of Prostate Cancer: To Treat or Not to Treat.

Sternberg IA, Vela I, Scardino PT.

Annu Rev Med. 2016;67:119-35. doi: 10.1146/annurev-med-060413-112226. Epub 2015 Oct 29. Review.

PMID:
26515982
15.

[Novel preclinical models and biomarkers for prostate cancer].

Korzeniewski N, Tapia-Laliena M, Tolstov Y, Pahernik S, Hadaschik B, Hohenfellner M, Duensing S.

Urologe A. 2013 Sep;52(9):1256-60. doi: 10.1007/s00120-013-3310-6. Review. German.

PMID:
23942741
16.

Molecular and genetic prognostic factors of prostate cancer.

Chakravarti A, Zhai GG.

World J Urol. 2003 Sep;21(4):265-74. Epub 2003 Aug 9. Review.

PMID:
12910365
17.

Tissue biomarkers for prostate cancer radiation therapy.

Tran PT, Hales RK, Zeng J, Aziz K, Salih T, Gajula RP, Chettiar S, Gandhi N, Wild AT, Kumar R, Herman JM, Song DY, DeWeese TL.

Curr Mol Med. 2012 Jul 1;12(6):772-87. Review.

18.

Genomic and Histopathological Tissue Biomarkers That Predict Radiotherapy Response in Localised Prostate Cancer.

Wilkins A, Dearnaley D, Somaiah N.

Biomed Res Int. 2015;2015:238757. doi: 10.1155/2015/238757. Epub 2015 Oct 4. Review.

19.

Incorporating genomics into breast and prostate cancer screening: assessing the implications.

Chowdhury S, Dent T, Pashayan N, Hall A, Lyratzopoulos G, Hallowell N, Hall P, Pharoah P, Burton H.

Genet Med. 2013 Jun;15(6):423-32. doi: 10.1038/gim.2012.167. Epub 2013 Feb 14. Review.

20.

Systematic, evidence-based discovery of biomarkers at the NCI.

Prensner JR, Chinnaiyan AM, Srivastava S.

Clin Exp Metastasis. 2012 Oct;29(7):645-52. doi: 10.1007/s10585-012-9507-z. Epub 2012 Aug 7. Review.

Supplemental Content

Support Center